GLP1R and COVID-19: In a multinational retrospective cohort study, Nyland et al. examined usage of GLP1-Ra, DPP-4i, pioglitazone prescribed with at least 6 months preceding the first record of COVID-19, in relation to the incidence of hospital admissions, respiratory complications, and mortality within 28 days after a COVID-19 diagnosis.